MedPath

ONCOC4, INC.

ONCOC4, INC. logo
🇦🇺Australia
Ownership
Private
Established
2020-01-01
Employees
11
Market Cap
-
Website
http://oncoc4.com

Clinical Trials

8

Active:3
Completed:0

Trial Phases

3 Phases

Phase 1:6
Phase 2:1
Phase 3:1

Drug Approvals

0

Drug Approvals

No drug approvals found

This company may not have drug approvals in our database

Clinical Trials

Distribution across different clinical trial phases (8 trials with phase data)• Click on a phase to view related trials

Phase 1
6 (75.0%)
Phase 2
1 (12.5%)
Phase 3
1 (12.5%)

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2024-10-10
Last Posted Date
2025-07-23
Lead Sponsor
OncoC4, Inc.
Target Recruit Count
204
Registration Number
NCT06635785
Locations
🇺🇸

University of Alabama at Birmingham, Birmingham, Alabama, United States

🇺🇸

Highlands Oncology Group, Springdale, Arkansas, United States

🇺🇸

University of Florida UF Health Cancer Center, Gainesville, Florida, United States

and more 14 locations

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Phase 1
Recruiting
Conditions
Advanced Solid Tumor
Interventions
First Posted Date
2024-04-08
Last Posted Date
2025-03-05
Lead Sponsor
OncoC4, Inc.
Target Recruit Count
30
Registration Number
NCT06352359
Locations
🇺🇸

University of California at Davis Cancer Center, Sacramento, California, United States

🇺🇸

UF Health Cancer Center, University of Florida, Gainesville, Florida, United States

🇺🇸

AdventHealth Medical Group Oncology Research at Celebration, Kissimmee, Florida, United States

and more 5 locations

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Phase 1
Withdrawn
Conditions
Advanced Solid Tumor
Interventions
Other: Placebo
First Posted Date
2024-01-23
Last Posted Date
2024-04-03
Lead Sponsor
OncoC4, Inc.
Registration Number
NCT06219499

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Phase 1
Active, not recruiting
Conditions
Melanoma
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
High Grade Serous Adenocarcinoma of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Endometrial Cancer
Cervical Cancer
Renal Cell Carcinoma
Bladder Cancer
Interventions
First Posted Date
2023-05-15
Last Posted Date
2025-02-03
Lead Sponsor
OncoC4, Inc.
Target Recruit Count
18
Registration Number
NCT05858736
Locations
🇦🇺

St. Vincent's Private Hospital, Darlinghurst, New South Wales, Australia

🇦🇺

Mater Misericordiae Ltd., Brisbane, Queensland, Australia

🇦🇺

Tasman Oncology Research, Southport, Queensland, Australia

and more 2 locations

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Phase 1
Recruiting
Conditions
Metastatic Castration-resistant Prostate Cancer
Interventions
Drug: ONC-392 low
Drug: ONC-392 high
First Posted Date
2023-01-12
Last Posted Date
2025-04-08
Lead Sponsor
OncoC4, Inc.
Target Recruit Count
141
Registration Number
NCT05682443
Locations
🇺🇸

UC Davis Comprehensive Cancer Center, Sacramento, California, United States

🇺🇸

Rocky Mountain Cancer Centers USOR, Aurora, Colorado, United States

🇺🇸

Moffitt Cancer Cancer, Tampa, Florida, United States

and more 20 locations
  • Prev
  • 1
  • 2
  • Next

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.